Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes eahanced antitumor activity

Cancer Research

Volumn 64, Issue 16, 2004, Pages 5850-5860

  Whitmore, Mark M ^a   DeVeer, Michael J ^b   Edling, Andrea ^a   Oates, Rhonda K ^a   Simons, Brenna ^a   Lindner, Daniel ^a   Williams, Bryan R G ^a,c  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; BETA INTERFERON; DOUBLE STRANDED DNA; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEUTRALIZING ANTIBODY; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OLIGODEOXYNUCLEOTIDE DERIVATIVE; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN P40; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL STRAIN; CELL STRAIN 293 T; CORRELATION ANALYSIS; CPG ISLAND; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA SEQUENCE; DRUG EFFECT; DRUG POTENTIATION; DRUG RESEARCH; DRUG SCREENING; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; IN VIVO STUDY; KNOCKOUT MOUSE; LUNG METASTASIS; LUNG PARENCHYMA; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; SPLEEN; UPREGULATION; VACCINATION; VIRUS;

ANIMALS; CELL LINE; CPG ISLANDS; DENDRITIC CELLS; DNA; DNA-BINDING PROTEINS; ENZYME ACTIVATION; HUMANS; INTERFERON TYPE I; INTERLEUKIN-12; INTERLEUKIN-6; INTERLEUKIN-8; LUNG; MACROPHAGE ACTIVATION; MACROPHAGES; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; POLY I-C; PROMOTER REGIONS (GENETICS); RECEPTORS, CELL SURFACE; RNA, DOUBLE-STRANDED; TOLL-LIKE RECEPTOR 9; TOLL-LIKE RECEPTORS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4143131229     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0063     Document Type: Article

References (73)

1. Ahmad-Nejad P, Hacker H, Rutz M, et al. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002;32:1958-68.
2. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227-64.
3. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature (Lond) 2000;406:782-7.
4. MacMicking J, Xie Q-W, Nathan CF. Nitric oxide and macrophage function. Annu Rev Immunol 1997;15:323-50.
5. Leitner WW, Hwang LN, De Veer MJ, et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 2003;9:33-9.
6. Whitmore MM, Li S, Falo L Jr, Huang L. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol Immunother 2001;50:503-14.
7. Lanuti M, Rudginsky S, Force SD, et al. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Res 2000;60:2955-63.
8. Leitner WW, Ying H, Driver DA, Dubensky TW, Restifo NP. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res 2000;60:51-5.
9. Ying H, Zaks TZ, Wang RF, et al. Cancer therapy using a self-replicating RNA vaccine. Nat Med 1999;5:823-7.
10. Scheule RK. The role of CpG motifs in immunostimulation and gene therapy. Adv Drug Deliv Rev 2000;44:119-34.
11. McCluskie MJ, Weeratna RD, Davis HL. The role of CpG in DNA vaccines. Springer Semin Immunopathol 2000;22:125-32.
12. Paludan SR, Mogensen SC. Virus-cell interactions regulating induction of tumor necrosis factor alpha production in macrophages infected with herpes simplex virus. J Virol 2001;75:10170-8.
13. Smith EJ, Marie I, Prakash A, Garcia-Sastre A, Levy DE. IRF3 and IRF7 phosphorylation in virus-infected cells does not require double-stranded RNA-dependent protein kinase R of Ikappa B kinase but is blocked by vaccinia virus E3L protein. J Biol Chem 2001;276:8951-7.
14. Clarke PA, Mathews MB. Interactions between the double-stranded RNA binding motif and RNA: definition of the binding site for the interferon-induced protein kinase DAI (PKR) on adenovirus VA RNA. RNA 1995;1:7-20.
15. Desai SY, Patel RC, Sen GC, et al. Activation of interferon-inducible 2′-5′ oligoadenylate syntbetase by adenoviral VAI RNA. J Biol Chem 1995;270:3454-61.
16. Burge C, Campbell AM, Karlin S. Over- and under-representation of short oligonucleotides in DNA sequences. Proc Natl Acad Sci USA 1992;89:1358-62.
17. Karlin S, Doerfler W, Cardon LR. Why is CpG suppressed in the genomes of virtually all small eukaryotic viruses but not in those of large eukaryotic viruses? J Virol 1994;68:2889-97.
18. Krieg AM, Wu T, Weeratna R, et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA 1998;95:12631-6.
19. Zheng M, Klinman DM, Gierynska M, Rouse BT. DNA containing CpG motifs induces angiogenesis. Proc Natl Acad Sci USA 2002;99:8944-9.
20. Krug A, Luker GD, Barchet W, et al. Herpes simplex virus type 1 (HSV-1) activates murine natural interferon-producing cells (IPC) through Toll-like receptor 9. Blood 2004;103:1433-7.
21. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 2003;198:513-20.
22. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature (Lond) 2001;413:732-8.
23. Kumar A, Yang YL, Flati V, et al. Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF-kappaB. EMBO J 1997;16:406-16.
24. Khabar KS, Dhalla M, Siddiqui Y, et al. Effect of deficiency of the double-stranded RNA-dependent protein kinase, PKR, on antiviral resistance in the presence or absence of ribonuclease L: HSV-1 replication is particularly sensitive to deficiency of the major IFN-mediated enzymes. J Interferon Cytokine Res 2000;20:653-9.
25. Zhou A, Paranjape J, Brown TL, et al. Interferon action and apoptosis are defective in mice devoid of 2′,5′-oligoadenylate-dependent RNase L. EMBO J 1997;16:6355-63.
26. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature (Lond) 2000;408:740-5.
27. Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001;98:9237-42.
28. Stuehr DJ, Nathan CF. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989;169:1543-55.
29. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997;9:10-6.
30. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science (Wash DC) 1996;272:50-3.
31. Brittenden J, Heys SD, Ross J, Eremin O. Natural killer cells and cancer. Cancer (Phila) 1996;77:1226-43.
32. Herberman RB. Cancer immunotherapy with natural killer cells. Semin Oncol 2002;29:27-30.
33. Cowdery JS, Boerth NJ, Norian LA, Myung PS, Koretzky GA. Differential regulation of the IL-12 p40 promoter and of p40 secretion by CpG DNA and lipopolysaccharide. J Immunol 1999;162:6770-5.
34. Overbergh L, Valckx D, Waer M, Mathieu C. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 1999;11:305-12.
35. Toshchakov V, Jones BW, Perera PY, et al. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat Immunol 2002;3:392-8.
36. Cowdery JS, Chace JH, Yi AK, Krieg AM. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol 1996;156:4570-5.
37. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
38. Slinker BK. The statistics of synergism. J Mol Cell Cardiol 1998;30:723-31.
39. Ohmori Y, Hamilton TA. Requirement for STAT1 in LPS-induced gene expression in macrophages. J Leukocyte Biol 2001;69:598-604.
40. Brehm G, Kirchner H. Analysis of the interferons induced in mice in vivo and in macrophages in vitro by Newcastle disease virus and by polyinosinic-polycytidylic acid. J Interferon Res 1986;6:21-8.
41. Peters KL, Smith HL, Stark GR, Sen GC. IRF-3-dependent, NFkappa B- and JNK-independent activation of the 561 and IFN-beta genes in response to double-stranded RNA. Proc Natl Acad Sci USA 2002;99:6322-7.
42. Li M, Muller J, Xu F, Hearing VJ, Gorelik E. Inhibition of melanoma-associated antigen expression and ecotropic retrovirus production in B16BL6 melanoma cells transfected with major histocompatibility complex class I genes. Cancer Res 1996;56:4464-74.
43. Chiang EY, Henson M, Stroynowski I. Correction of defects responsible for impaired Qa-2 class lb MHC expression on melanoma cells protects mice from tumor growth. J Immunol 2003;170:4515-23.
44. Goldszmid RS, Idoyaga J, Bravo AI, et al. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol 2003;171:5940-7.
45. Mellits KH, Kostura M, Mathews MB. Interaction of adenovirus VA RNA1 with the protein kinase DAI: nonequivalence of binding and function. Cell 1990;61:843-52.
46. Khoo D, Perez C, Mohr I. Characterization of RNA determinants recognized by the arginine- and proline-rich region of Us11, a herpes simplex virus type 1-encoded double-stranded RNA binding protein that prevents PKR activation. J Virol 2002;76:11971-81.
47. Xiang Y, Condit RC, Vijaysri S, et al. Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus. J Virol 2002;76:5251-9.
48. Huerta-Yepez S, Vega M, Jazirehi A, et al. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappaB and inhibition of Bcl-(xL) expression. Oncogene 2004;23:4993-5003.
49. Bhaumik S, Khar A. Cytokine-induced production of NO by macrophages induces apoptosis and immunological rejection of AK-5 histiocytic tumor. Apoptosis 1998;3:361-8.
50. Chawla-Sarkar M, Bauer JA, Lupica JA, et al. Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. J Biol Chem 2003;278:39461-9.
51. Scheffer SR, Nave H, Korangy F, et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer 2003;103:205-11.
52. Xu F, Carlos T, Li M, et al. Inhibition of VLA-4 and up-regulation of TIMP-1 expression in B16BL6 melanoma cells transfected with MHC class I genes. Clin Exp Metastasis 1998;16:358-70.
53. Lieberman LA, Hunter CA. Regulatory pathways involved in the infection-induced production of IFN-gamma by NK cells. Microbes Infect 2002;4:1531-8.
54. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
55. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:155-68.
56. Basse PH, Whiteside TL, Chambers W, Herberman RB. Therapeutic activity of NK cells against tumors. Int Rev Immunol 2001;20:439-501.
57. Banchereau J, Paczesny S, Blanco P, et al. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci 2003;987:180-7.
58. Feng SH, Lo SC. Lipid extract of Mycoplasma penetrans proteinase K-digested lipid-associated membrane proteins rapidly activates NF-kappaB and activator protein I. Infect Immun 1999;67:2951-6.
59. Udalova IA, Kwiatkowski D. Interaction of AP-1 with a cluster of NF-kappa B binding elements in the human TNF promoter region. Biochem Biophys Res Commun 2001;289:25-33.
60. Ma W, Gee K, Lim W, et al. Dexamethasone inhibits IL-12p40 production in lipopolysaccharide-stimulated human monocytic cells by down-regulating the activity of c-Jun N-terminal kinase, the activation protein-1, and NF-kappaB transcription factors. J Immunol 2004;172:318-30.
61. Naumann M, Wessler S, Bartsch C, Wieland B, Meyer TF. Neisseria gonorrhoeae epithelial cell interaction leads to the activation of the transcription factors nuclear factor kappaB and activator protein 1 and the induction of inflammatory cytokines. J Exp Med 1997;186:247-58.
62. Lowenstein CJ, Alley EW, Raval P, et al. Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon gamma and lipopolysaccharide. Proc Natl Acad Sci USA 1993;90:9730-4.
63. Kirchhoff S, Wilhelm D, Angel P, Hauser H. NFkappaB activation is required for interferon regulatory factor-1- mediated interferon beta induction. Eur J Biochem 1999;261:546-54.
64. Ludwig S, Ehrhardt C, Neumeier ER, et al. Influenza virus-induced AP-1-dependent gene expression requires activation of the JNK signaling pathway. J Biol Chem 2001;276:10990-8.
65. Yamamoto M, Sato S, Mori K, et al. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 2002;169:6668-72.
66. Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science (Wash DC) 2003;301:640-3.
67. Byrnes AA, Ma X, Cuomo P, et al. Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunity. Eur J Immunol 2001;31:2026-34.
68. Scharton-Kersten T, Contursi C, Masumi A, Sher A, Ozato K. Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction. J Exp Med 1997;186:1523-34.
69. Hacker H, Vabulas RM, Takeuchi O, et al. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med 2000;192:595-600.
70. Schnare M, Holt AC, Takeda K, Akira S, Medzhitov R. Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88. Curr Biol 2000;10:1139-42.
71. Jiang Z, Zamanian-Daryoush M, Nie H, et al. Poly(dI.dC)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFkappa B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR. J Biol Chem 2003;278:16713-9.
72. Sweet MJ, Stacey KJ, Kakuda DK, Markovich D, Hume DA. IFN-gamma primes macrophage responses to bacterial DNA. J. Interferon Cytokine Res 1998;18:263-71.
73. Gao JJ, Zuvanich EG, Xue Q, et al. Cutting edge: bacterial DNA and LPS act in synergy in inducing nitric oxide production in RAW 264.7 macrophages. J Immunol 1999;163:4095-9.